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P u r p o s e :  To describe the clinical features and genetic analysis of a family with an autosomal dominant cone dystrophy 
(adCD).
M e t h o d s :  Selected members of a family with an autosomal dominant cone dystrophy underwent ophthalmic evaluation.
Blood samples were obtained, genomic DNA was isolated, and genomic fragments were amplified by PCR. Linkage to 
locus D6S1017 was established. DHPLC mutational analysis and direct sequencing were used to identify a mutation in 
GUCA1A, the gene encoding the guanylate cyclase activating protein 1 (GCAP1).
R e s u lts :  Of 24 individuals who are at risk of the disease in a five generation family, 11 members were affected. Clinical 
presentations included photophobia, color vision defects, central acuity loss, and legal blindness with advanced age. The 
disease phenotype was observed in the second and third decades of life and segregated in an autosomal dominant fashion.
An electroretinogram performed on one proband revealed profoundly subnormal and prolonged photopic and flicker 
responses, but preserved scotopic ERGs, consistent with a cone dystrophy. Mutational analysis and direct sequencing 
revealed a C451T transition in GUCA1A, corresponding to a novel L151F mutation in GCAP1. Like the E155G mutation, 
this mutation occurs in the EF4 hand domain, a region of GCAP1 critical in conferring calcium sensitivity to the protein.
The leucine at this position is highly conserved among vertebrate guanylate cyclase activating proteins.
C o n c lu s io n s :  A novel L151F missense mutation in the EF4 high affinity Ca2+ binding site of GCAP1 is linked to adCD in 
a large pedigree. The cone dystrophy in this family shares clinical and electrophysiologic characteristics with other previ­
ously described adCD caused by mutations in GUCA1A.
The cone dystrophies are a phenotypically heterogeneous 
group of hereditary retinal degenerations characterized by pro­
gressive dysfunction of the photopic (cone mediated) system, 
presenting with hemeralopia (day blindness), loss of color vi­
sion, reduced central visual acuity, and preserved peripheral 
vision [1]. Cone dystrophies may be contrasted to rod dystro­
phies, such as retinitis pigmentosa, which are characterized 
by abnormalities in scotopic (rod mediated) functions, mani­
festing as night blindness, preserved central visual acuity early 
in the disease process, and constricted peripheral vision. Early 
in the disease process, the fundus appearance of a patient with 
a cone dystrophy may be normal. The disease is then diag­
nosed based on characteristic changes in the electroretinogram.
Later in the disease process, the retinal pigment epithelium 
may take on a granular appearance that may progress to cen­
tral atrophy.
Like retinis pigmentosa (RP), the cone dystrophies are 
genetically heterogeneous and may present as a sporadic, au­
tosomal dominant, autosomal recessive, or X-linked recessive 
trait (RetNet). Identified genes linked to autosomal dominant
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cone dystrophies include GUCY2D, encoding photoreceptor 
guanylate cyclase 1 (retGC-1, or GC1) and GUCA1A, encod­
ing the photoreceptor specific Ca2+ binding protein termed 
guanylate cyclase activating protein 1 (GCAP1). GC1 and 
GCAP1 are key components in the phototransduction cascade 
in rod and cone photoreceptors. In the dark adapted state, pho­
toreceptors have high levels of cGMP and this molecule holds 
photoreceptor plasma membrane cation channels open. Ex­
posure to light initiates the phototransduction cascade in pho­
toreceptors, resulting in the hydrolysis of cGMP and closure 
of the cGMP-gated cation channels [2-4]. The concentration 
of free intracellular Ca2+ decreases as a consequence of con­
tinued activity of the Na+/Ca2+-K+ exchanger (NCKX) ex­
changer also located in the plasma membrane, an event that in 
turn activates guanylate cyclases [4]. The stimulation of the 
guanylate cyclases by decreased levels of calcium occurs in­
directly via GCAPs [5-7]. The GCAP-stimulated GC activity 
eventually returns cGMP to levels that are sufficient to re­
open the cGMP-gated cation channels, establishing the dark 
adapted state.
The GCAPs are neuron specific calcium binding proteins 
(NCBPs), a subgroup of the large calmodulin supergene fam­
ily with four EF hand [8] motifs [9]. NCBPs include recoverins, 
another set of photoreceptor specific Ca2+ binding proteins, 
frequenins, hippocalcins and hippocalcin-like proteins, neu-
M olecular Vision 2005; 11:143-51 <http://www.molvis.org/molvis/v11/a16> ©2005 M olecular Vision
ronal Ca2+ sensors and many others [10]. Unlike calmodulin 
and other NCBPs, the GCAPs activate their target proteins, 
the guanylate cyclases, when the concentration of free intrac­
ellular Ca2+ is low [11], while other NCBPs activate their tar­
gets when the concentration of free Ca2+ is high. Up to eight 
GCAPs have been identified in vertebrates [12], but in human 
retina there are only three (GCAP1, GCAP2, and GCAP3). 
The mouse appears to express only GCAP1 and GCAP2, but 
not GCAP3 [11,13]. The human and mouse GCAP1 and 
GCAP2 genes reside in a tail-to-tail array on chromosome 
6p21.1 and chromosome 17, respectively, and share a four- 
exon/three-intron arrangement [14,15]. GCAP3 has the same 
exon/intron arrangement, but has been localized to 3q13.1 [11]. 
Thus, it appears that these three GCAP genes arose as a result 
of the duplication and translocation of a common ancestral 
gene.
Four different mutations linked to retina disease have been 
previously described in GCAP1 (Y99C, P50L, E155G, and 
I143NT) [16-20]. All are missense mutations, one (I143NT) 
has an insertion of an additional amino acid residue. Loss of 
Ca2+ sensitivity is associated with the Y99C, E155G, and 
I143NT mutations. Common to these is that the mutation af­
fects one of the three functional EF hand motifs in GCAP1 
(EF3 or EF4). The biochemical effect of the mutations con­
sists of the inability of the mutant GCAPs to inhibit photore­
ceptor GC in the dark, when Ca2+ is elevated [21,22]. The re­
sult is that cGMP levels are elevated in mutant photorecep­
tors, and a larger number of cation channels remain open, which 
eventually leads to elevated Ca2+ concentration and to photo­
receptor cell death [23]. In this manuscript, we describe the 
clinical features of and the genetic mutations in a family with 
an autosomal dominant cone dystrophy carrying a novel mis­
sense mutation in the GUCA1 gene.
M ETHO DS
Patients: This study was approved by the Institutional Re­
view Board of the University of Utah Hospitals and Clinics 
and all subjects provided informed consent prior to participa­
tion. Some subjects underwent complete ophthalmologic ex-
T a b le  1 . O l i g o n u c l e o t i d e  p r im e r s  u s e d  f o r  a m p l i f i c a t io n  a n d  
SEQUENCING OF EXONS 1 -4  OF THE HUMAN G U C A 1 A  (G C A P 1 )  GENE
T a b l e  2 .  A c c e ssio n  n u m b er s  o r  r e f e r e n c e s  fo r  G C A P  s e ­
q u en c es  u se d  in  t h e  a l ig n m e n t  o f  F ig u r e  F ig u r e  3 B
E x o n
G C A P1_1F 
GCA P1_1R 
G C A P1_2F 
GCA P1_2R 
G C A P1_3F 
GCA P1_3R 
G C A P1_4F 
GCAP1 4R
P r i m e r  s e q u e n c e
5'-G G CCTG TCCA TCTCAG ACGT-3'
5'-CCCCAGCTGGTCAGGCTTCCAG-3'
5'-GCCTGAGGCTGGAGTGAGCG-3'
5'-C TAACCCTGG GCTCTCA GTTCC-3'
5'-CCTGAGATAGGATAAGGATGG-3'
5'-ACCCCA CATCCATGG TGA CC-3'
5'-CTGGACTGCAGAAATGAACACCCTC-3'
5'-GGCGAGCTAAGCCTCTGAGTTC-3'
Primers marked with “F” are forward (sense) primers, while those 
marked with “R” are reverse (antisense) primers. Amplicons gener­
ated with F/R pairs were directly sequenced to identify mutations in 
the GCAP1 gene.
Name Species Source
bGCAP1 Bos taurus AAB31698
hGCAP1 Homo sapiens NP_000400




cGCAP1 Gallus gallus P7988C
fGCAP1 Rana pipiens O73761
zGCAP1 Danio reric AAK95947








bGCAP2 Bos taurus L43001
hGCAP2 Homo sapiens 8928106





cGCAP2 Gallus gallus P79881








fuGCAP2 Fugu rubripes CAD12 7 8 0
zGCAP2 Danio rerio AAK95948
hGCAP3 Homo sapiens AAD19944
zGCAP3 Danio rerio AAK95949
zGCAP4 Danio rerio AY850384
zGCAP5 Danio rerio AY850385
zGCAP7 Danio rerio AY850386
fGCIP Rana pipiens O7 3 7 63
fuguGCIP Fugu rubripes [12]
Up to eight GCAP genes have been identified in vertebrates (mam­
mals, fishes, and amphibia). One sequence (sbGCAP2, from M. 
saxatiolis) is unpublished, and one sequence (fuguGCIP), derived 
from genomic contigs as described in [12], is not available from 
Genbank.
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Figure 1. Identification of the GUCA1A mutation in an American 
Pedigree. A: Pedigree of the study family. Individuals are identified 
by pedigree number. Squares indicate males, circles indicate females, 
slashed symbols indicate deceased, solid symbols indicate affected 
individuals, open symbols indicate unaffected individuals, +/+ indi­
cates two copies of wild type GUCA1A, M/+ indicates one copy of 
wild type GUCA1A, one copy of mutant GUCA1A. The proband ana­
lyzed in this study is identified by an arrow. B: Electroretinogram 
(ERG) obtained from individual IV:1. Traces obtained from the study 
subject are shown in the right column. Traces from a normal subject 
are shown in the left column for comparison. The scotopic ERGs 
obtained with blue, red, and white flashes are nearly normal (top 
three rows). The photopic ERG is non-recordable consistent with 
lack of cone function. 30 Hz flicker following is attenuated, but still 
recordable. These results are consistent with a diagnosis of cone dys­
trophy and are similar to electrophysiologic findings described in 
subjects with Y99C and E155G mutations in GUCA1A. C: Compari­
son of DNA sequences of the affected individual IV: 1 (top) to a nor­
mal control (bottom). The proband DNA revealed a C-to-T transi­
tion (boxed) at the beginning of in exon 4 of GUCA1A, resulting in a 
leucine to phenylalanine change (L151F) in GCAP1 (boxed). This 
mutation segregated with the disease phenotype and was not found 
in 200 normal controls.
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amination including visually acuity measurements and fun­
dus examinations. Other subjects were interviewed by tele­
phone. Blood samples were obtained by venipuncture. Patients 
were diagnosed with cone dystrophy if they showed the clas­
sic triad of photophobia, decreased color vision, and decreased 
visual acuity.
Electroretinography: One patient underwent electroret- 
inography. Electroretinograms (ERGs) were recorded using 
standard electrophysiologic methods (D. Creel, Clinical Elec­
trophysiology, Webvision). The subject was dark adapted for 
30 min. Reference and ground electrodes were each attached 
to an earlobe. Using an indirect headlamp with several Wratten 
26 red filters simulating a mobile dark room “safe” light, a 
Burian-Lawwill speculum contact lenses was inserted to record 
ERGs from the cornea. Responses were obtained using a 
Nicolet ganzfeld bowl, amplifier, and computer. Responses 
were differentially amplified (band pass 0.1-1000 Hz), aver­
aged, and stored. Amplitude band pass sensitivity was one 
millivolt. ERGs were recorded using single scotopically bal­
anced dim blue and red flashes, and bright white flashes. Pa­
tients were then light adapted with background illumination 
of 3.18x104 cd/m2 for 10 min and photopic ERGs were re­
corded using 30 Hz flicker following and the same bright white 
flash.
Genetic linkage and mutation screening: Genomic DNA 
was extracted from blood samples using a Qiagen DNA isola­
tion kit according to the m anufacturer’s specifications 
(QIAGEN, Valencia, CA). Linkage to microsatellite marker 
D6S1017, linked to the GCAP1 locus was assessed using es­
tablished methods [24]. Each of the four exons of GCAP1 
were then amplified by PCR using flanking intron specific 
primers (Table 1) and screened for mutations by denaturing 
high performance liquid chromatography (DHPLC; WAVE®
System, Transgenomic, Omaha, NE). Sequence alterations 
were identified by direct sequencing with a CEQ Dye Termi­
nator Cycle Sequencing Kit on Beckman-Coulter CEQ 8000 
Genetic Analysis System, according to the manufacturer’s in­
structions and using established methods [25,26].
Fundus photography: Fundus photographs and fluores­
cein angiography were performed using a TOPCON digital 
fundus camera according to the manufacturer’s specification 
(TOPCON America Corporation, Pleasanton, CA).
Sequence alignments: The alignments of FastA versions 
of GCAP amino acid sequences were generated by Clustal W 
(version 1.82). The GenBank accession numbers for the amino 
acid sequences are in Table 2.
RESULTS
Clinical evaluation o f the family with adCORD: The pedi­
gree consisted of 30 living members of a five generation fam­
ily (Figure 1A) in which the disease was inherited in an auto­
somal dominant pattern. Clinical characteristics of the family 
(Table 3) included photophobia, color vision defects and cen­
tral acuity loss. Most subjects within the family noted symp­
toms in the second and third decades of life. Visual acuity 
ranged from younger individuals with normal or nearly nor­
mal visual function to older individuals with legal blindness. 
Representative fundus photos from two individuals from this 
pedigree are presented in Figure 2. The proband IV:1 at age 
36 is mildly affected. Fundus examinations revealed only subtle 
pigmentary changes in the macula (Figure 2A,B). However, 
the fundus fluorescent angiogram of this individual (Figure 
2C,D) revealed more marked atrophic changes in the macula 
than can be seen on fundus examination. The mother of the 
proband at age 64 is more severely affected and has geographic 
atrophy of the retina and retinal pigment epithelium (Figure
Table 3. Clinical characteristics of individuals from study family
Age at
Current acuity Age at time of
Current onset of correct
Individual Gender age OD OS symptoms diagnosis
II:3 F <20/200 <20/200 3LOII F 88 <20/200 <20/200 5 40
III:2 F 64 20/400 20/400 20 16*
III:5 F 60 <20/300 <20/300 28 32
III:7 M 64 20/200 20/400 11 32
III:9 M 52 20/400 20/400 8 16
1>I M 38 20/40 20/50 24 *42
4>I M 24 20/40 20/40 8-13 24
6>I M 33 20/40 20/40 26 32O1>I F 36 20/400 20/200 14 25
11>I M 39 20/30 20/30 27 27
V:4 F 8 20/20 20/20 ** 6
In the “Age at time of correct diagnosis” column, the two individuals having a single asterisk were originally diagnosed with juvenile macular 
dystrophy. In the “Age at onset of symptoms” column, the symptoms include photophobia, decreased color vision, and decreased visual acuity. 
In this same column, the double asterisk indicates that this individual is asymptomatic, most likely due to her youth, though she has inherited 
an L151F mutation.
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Figure 2. Fundus photographs of affected subjects from the study family. A: Individual IV:1, age 36, with visual acuities of 20/40 in the right 
eye and 20/50 in the left eye. Color fundus photograph of the right eye. Subtle pigmentary changes are evident in the macula. B: Color fundus 
photograph of the left eye show similar changes. C: Fundus fluorescein angiogram of the right eye. Taken at 5:42 min after injection of sodium 
fluorescein, this photographic method reveals more marked changes in the retina that are not immediately evident in the color photographs. 
Areas of brightness within the macula (arrows) are referred to as “window defects” and represent areas of retinal and retinal pigment epithe­
lium atrophy. D: Fundus fluorescein angiogram of the left eye taken at 6:22 min after injection shows similar changes. E,F: Color fundus 
photographs from the more severely affected mother of the subject depicted in Figure 2. Individual III:2, age 64, has visual acuities of 20/400 
in the right eye and 20/400 in the left eye. E: Color fundus photograph of the right eye reveals atrophy of the macula. F: Color fundus 
photographs of the left eye reveal similar changes. The peripheral retina looks normal.
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2E,F).
The dim blue scotopic ERG response (mostly rod re­
sponse) of the proband is essentially normal. The dim red sc- 
otopic ERG predominantly reflects rod activity, but also re­
flects some cone activity. Thus the normal subject’s dim red 
ERG has an a-wave, an early, small b-wave labeled bx, and 
oscillatory potentials on the ascending limb of the b-wave. 
The early a-wave, bx-wave, and oscillatory potentials reflect 
cone activity, and these responses are absent in the proband’s 
ERG. The scotopic bright white ERG is minimally abnormal 
with an attenuated b-wave amplitude and slow implicit time. 
The 30 Hz flicker response and the photopic white ERG were 
profoundly subnormal and prolonged. Electrophysiologically, 
the manifestations of the L151F phenotype closely resemble 
that of the Y99C, E155G, and I143NT mutations where pho­
topic responses and flickers were non-recordable [16,19,20]. 
Rod responses and maximal dark adapted single white flash 
responses were only mildly subnormal in amplitude.
Genetic analysis: An initial genotype analysis with marker 
D6S1017 yielded a LOD score of 3.3 at 0=0.00, consistent 
with linkage to GUCA1A. Subsequently, DHPLC mutation 
screening and direct sequencing identified a C451T transition 
resulting in a novel L151F change in the GCAP1 amino acid 
sequences in all affected individuals (Figure 1C). This muta­
tion segregated with the disease phenotype and was not found 
in 200 normal controls. Like the E155G [16] and the I143NT 
[20] mutation, the L151F mutation occurs within the fourth 
EF-hand domain of GCAP1.
d i s c u s s i o n
Progressive cone dystrophies are inherited in an autosomal 
recessive, autosomal dominant, or X-linked fashion, and are 
caused by a heterogeneous set of genes (Table 4) [1]. These
genes include phototransduction genes like GNAT2, which 
encodes the cone transducin subunit, the CNGA3 and CNGB3 
genes, which encode subunits of the cGMP-gated cation chan­
nel, and the genes GUC2D and GUC1A, which encode GC1 
and GCAP1. Also contained in this group are transcription 
factors (CRX), genes involved in the retinoid cycle (ABCA4, 
RDH5), and genes involved in protein transport through the 
cilium (RPGR and RPGRIP). A number of loci are known for 
which the corresponding gene has yet to be identified (RetNet).
We have described the clinical features of twelve sub­
jects in a five generation family with an autosomal dominant 
cone dystrophy (Table 3). This disease was found to be caused 
by a novel mutation in GUCA1A affecting the EF4 high affin­
ity Ca2+ binding site of GCAP1. The phenotype of affected 
family members carrying the L151F mutation is clinically very 
similar to three of the four previously described mutations in 
GUCA1A. Initial symptoms of reduced central acuity and loss 
of color vision became apparent in the second and third de­
cades. It appears that all affected individuals eventually 
progress to legal blindness, with visual acuities between 20/ 
200 and 20/400. Funduscopic changes were initially subtle, 
but progressed to central atrophy over time. The L151F phe­
notype resembles the Y99C mutation in severity, but the age 
of onset of clinical symptoms is somewhat earlier in patients 
with the L151F mutation.
EF hands represent high affinity Ca2+ binding sites and 
are responsible for the calcium sensitivity of the GCAP/GC 
system. Not surprisingly, mutations within these domains were 
shown to alter calcium sensitivity [16,21,22]. Some of the 
amino acids within the domain contain oxygen in their side 
chains that facilitate calcium coordination [27,28]. Although 
the L151 residue does not directly participate in calcium bind­
ing, the L151F mutation affects the structure of the EF-hand
T able 4 . G enetic loci associated with progressive cone dystrophies
Inheritance Locus Symbol OMIM Gene Reference
AR 1p13.3 139340 GNAT2 [33]
AR 1p22.1 CORD3 604116 ABCA4 [34]
AR 1q12-q2 4 CORD8 605549 [35]
AR 2q11.2 600053 CNGA3 [36]
AD 6p21.1 COD3 602093 GUCA1A [19]
AD 6q13 CORD7 60364 9 RIMS1 [37]
AD 6q25-26 180020 RCD1 [38]
AR 8q21.3 605080 CNGB3 [39]
AR 12q13.3 601617 RDH5 [40]
AD 17p13.1 CORD6 601777 GUCY2D [41]
18q21.1-q21.3 CORD1 60 0 624 [42]
AD 19q13.3 CORD2 12 0 97 0 CRX [43]
XR Xp11.4 CORDX1 304020 RPGR [25]
XR Xp11.4-q13.1 CORDX3 300476 [44]
XR Xq2 7 CORDX2 300085 [45]
The table lists the inheritance mode (AR represents autosomal recessive; AD represents autosomal dominant; XR represents X-linked reces­
sive), the chromosomal localization (“Locus”), the disease nomenclature from RetNet, the Online Mendelian Inheritance in Man (OMIM) 
accession number, a gene symbol, and a reference.
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domain and thereby affects calcium sensitivity [29]. Review 
of the sequences of 30 GCAPs in 8 vertebrate species (Figure 
3) revealed that the L151 residue is highly conserved. Only 
the more distantly related GCAP6-8 of pufferfish and the 
guanylate cyclase-inhibitory proteins (GCIPs) carry a chemi­
cally similar isoleucine at this position. The presence of iso­
leucine is not considered to interfere with Ca2+ binding to EF4 
since it conforms with the EF hand consensus sequence [30]. 
Replacement of L151 by phenylalanine is also considered a 
conservative substitution since both Leu and Phe are hydro­
phobic and not much different in size [29]. However, even 
conservative substitutions can alter binding of Ca2+ to EF hand 
loops significantly. For example, An E155D mutant of GCAP 1 
(replacement of an acidic Glu by another acidic residue, Asp), 
drastically reduced Ca2+ sensitivity of E155D-GCAP1 [31].
We conclude that the L151F mutation is pathogenic for 
the following reasons. First, the mutation segregates with dis­
ease in a large five generation pedigree with 30 family mem­
bers. Second, this mutation was not found in over 200 con­
trols. Third, the mutation affects the high affinity Ca2+ binding 
site EF4, which has been shown to be key for Ca2+ sensitivity 
of GCAP1 in vitro [31,32]. Fourth, two other mutations in 
EF4 have been linked to dominant cone dystrophy [16,20]. 
Fifth, the L151F mutations was found to be pathogenic in an 
autosomal dominant cone/rod dystrophy in an unrelated pedi­
gree [29].
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